Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Rudolf Mierau1, Pia Moinzadeh2, Gabriela Riemekasten3, Inga Melchers4, Michael Meurer5, Frank Reichenberger6, Michael Buslau7, Margitta Worm9, Norbert Blank10, Rüdiger Hein11, Ulf Müller-Ladner12, Annegret Kuhn13,14, Cord Sunderkötter14, Aaron Juche15, Christiane Pfeiffer16, Christoph Fiehn17, Michael Sticherling18, Percy Lehmann19, Rudolf Stadler20, Eckhard Schulze-Lohoff21, Cornelia Seitz22, Ivan Foeldvari23, Thomas Krieg2, Ekkehard Genth24 and Nicolas Hunzelmann2

Abstract

Introduction: In the present study, we analysed in detail nuclear autoantibodies and their associations in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry.

Methods: Sera of 863 patients were analysed according to a standardised protocol including immunofluorescence, immunoprecipitation, line immunoassay and immunodiffusion.

Results: Antinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least one of the autoantibodies highly associated with SSc or with overlap syndromes with scleroderma features was detected, that is, anti-centromere (35.9%) or anti-topoisomerase I (30.1%), followed in markedly lower frequency by antibodies to PM-ScI (4.9%), U1-ribonucleoprotein (U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%), aminocycl-transfer RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional autoantibodies were detected in 55.4% of the patients with SSc, of which anti-Ro/anti-La, anti-mitochondrial and anti-p25/p23 antibodies were most frequent. The coexistence of SSc-associated and other autoantibodies was common (43% of patients). SSc-associated autoantibodies disclosed characteristic associations with clinical features of patients, some of which were previously not acknowledged.

Conclusions: This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-ScI, U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and characterise around 79% of all SSc patients in a central European cohort. These data confirm and extend previous data underlining the central role of the determination of ANAs in defining the diagnosis, subset allocation and prognosis of SSc patients.

Keywords: systemic sclerosis, scleroderma, autoantibodies, antinuclear antibodies
Introduction

Autoantibodies targeting characteristic nuclear antigens are one of the hallmarks of systemic sclerosis (SSc) [1-3]. The occurrence of different antinuclear antibodies (ANAs) is associated with distinct disease subtypes and with differences in disease severity, including extent of skin involvement, internal organ manifestation and prognosis. Although the current SSc criteria of the American College of Rheumatology [4] do not include the presence of ANAs, the detection of scleroderma-associated antibodies may be a valuable tool in the diagnosis of patients with very early SSc or only subtle symptoms [5,6]. For instance, in a recent study of patients with Raynaud’s phenomenon, the presence of ANAs (adjusted HR = 5.67) and SSc-associated antibodies (HR = 4.7) was the strongest independent predictor of definite SSc [6]. Some of the autoantibodies in SSc are regarded as disease-specific and can be correlated with genetic, demographic, diagnostic, clinical and prognostic aspects of the disease [1,3]. Therefore, autoantibodies are pivotal tools in the diagnosis of SSc by helping clinicians make decisions whether to perform further, more detailed and efficient diagnostic procedures, as well as decisions addressing disease management.

For frequently occurring antibodies such as anti-centromere (ACA) and anti-topoisomerase I (ATA), reliable detection systems based on ELISA or other binding tests have been developed. Other antibodies (that is, to fibrillarin, RNA polymerases (RNAPs) and so on) are not identified by common test procedures, but rather by laboratories able to perform sophisticated procedures to confirm the results on the basis of more than one independent method. Even for the most common autoantibodies, the choice of the detection method used is critical to the sensitivity and specificity of the results and hence their diagnostic value [7].

Researchers in numerous studies have examined the presence of antibodies to single predefined antigens in SSc and their clinical associations, whereas many of the investigators who have comprehensively examined large SSc patient cohorts have often restricted their autoantibody analyses to the most common SSc antibodies, ACA and ATA [8-12], or analysed only a few additional antibodies [13-17]. The aim of this study was therefore to characterise all known non-organ-specific, SSc-associated autoantibodies, as well as other, potentially new nuclear autoantibodies by using a standardised protocol in the large SSc patient cohort included in the German Network for Systemic Sclerosis Registry, and to correlate these findings with the clinical characteristics of these patients.

Materials and methods

Patients

Serum samples from 863 consecutive patients included in the German Network for Systemic Sclerosis Registry between 2004 and 2007 from 23 different clinical centres were analysed. Patient data are gathered and registered using a consensual registration form and reference documents with item definitions and recommendations for organ-specific diagnostic procedures as previously described [18,19]. Of the patients included, 82.9% were female, their mean age ± SD was 58.0 ± 13.4 years (median = 60 years, range 12 to 93). The patients’ age at disease onset ranged from 3 to 87 years (median = 49 years, mean = 47.7 ± 14.2).

The registry defines five subsets, that is, limited cutaneous and diffuse cutaneous SSc [20], overlap syndrome [21,22], systemic sclerosis sine scleroderma [23,24] and undifferentiated connective tissue disease with features of scleroderma [25,26], as recently described [18]. The latter subset corresponds largely to the subgroup ‘early SSc’ as described by LeRoy and Medsger [5] but may also include patients who will never develop definite SSc. The study, including the patients’ informed consent regarding data storage, was approved by the lead Ethics committee of the Cologne University Hospital and by the respective ethics committees of the contributing centres.

Autoantibody analysis

To detect SSc-associated autoantibodies in a comprehensive way, we used the search strategy commonly performed in diagnostic procedures for connective tissue diseases based on a HEp-2 cell immunofluorescence assay followed by tests using cellular extracts and/or recombinant antigens. This strategy is focused on circulating antibodies against non-organ-specific cellular autoantigens. Cell- or tissue-specific autoantibodies, which have also been described in scleroderma patients [3], were not included in the analytical protocol. At least one serum draw from each patient (N = 863) was analysed for circulating autoantibodies by a predefined protocol (Figure 1) with at least four assay systems performed in a single laboratory by a single group of technologists.

Indirect immunofluorescence using fluorescein isothiocyanate-conjugated goat anti-human immunoglobulin G was performed as a screening method for the detection of ANAs on HEp-2 cells (HEp-20-10; Euroimmun, Lübeck, Germany) seeded onto a microscope slide [27]. Titres of at least 1:80 dilution were regarded as positive. Different nuclear and cytoplasmic fluorescence patterns were documented.
A line immunoassay (EUROLINE ANA Profile 3; Euroimmun) was performed according to the manufacturer's instructions. This assay is able to detect, by binding to recombinant or purified antigens, the following autoantibodies: U1-ribonucleoprotein (U1-RNP), Sm, Ro60, Ro52, La (SS-B), Scl-70, PM-Scl, centromere protein B (CENP-B), proliferating cell nuclear antigen (PCNA), double-stranded DNA (dsDNA), nucleosomes, histones, ribosomal P proteins and the mitochondrial M2 antigen.

Immunoprecipitation (IP) of radiolabelled HeLa cell extract was performed as described [28,29] with slight modifications. In brief, HeLa S3 cells in suspension culture in methionine-deficient RPMI medium with 10% dialyzed foetal bovine serum were incubated with $^{35}$S methionine (to a final activity of 0.3 MBq/ml) overnight. They were (1) washed in Tris-buffered saline and (2) lysed by resuspension in IP buffer (10 mM Tris·HCl, pH 8.0, with 500 mM NaCl, 0.1% Igepal (Sigma, Munich, Germany) and 2 mM phenylmethylsulfonyl fluoride) and sonication on ice. IP was performed by incubation of patient sera (10 μl) with protein A Sepharose beads (2 mg in 500 μl; Sigma) for two hours, three short washing steps, end-over-end rotation with the radiolabelled cell extract overnight, five washing steps, separation of the precipitates on 5% to 20% gradient SDS-PAGE gels and subsequent autoradiography for six to ten days. Bands typical of autoantibodies were identified according to their apparent molecular weight and comigration with bands produced by reference sera with known autoantibody specificity. After we completed this procedure, the autoantibodies to the following antigens were routinely detectable: topoisomerase I (Scl-70), RNAPs (I and/or III), Ku, fibrillarin, To, NOR-90, PI-7, PI-12, EJ, OJ, KS, Mi-2, signal recognition particle, ribonucleoprotein (usually U1-RNP), SL, PCNA, ribosomal P proteins and p25/p23, also known as ‘anti-chromo’ [30,31]. In our hands, the detection of antibodies to Ro, La, PM-Scl, Jo-1, centromere antigens and the mitochondrial M2 antigen was unreliable by this method. Bands of unknown nature were registered and entered into the database of autoantibody results.

Immunodiffusion (ID) was performed in Agarose gels with rabbit and/or calf thymus extract (Pel-Freez Biologicals, Rogers, AR, USA) as described previously [32]. Autoantibodies were identified by the identity of precipitation lines with patient sera compared with monospecific prototype sera with known autoantibody specificity. The use of prototype serum was guided by results of the immunofluorescence pattern on HEp-2 cells. The following autoantibodies were detectable: topoisomerase 1 (Scl-70), PM-Scl, Ku, SL, Jo-1, PI-7, U1-RNP, Sm and La (SS-B). Precipitation bands that did not merge with any of the prototype sera were registered as unknown autoantibodies and entered into the database of autoantibody results.

In selected sera, confirmatory assays using recombinant or synthetic antigens (see Table 1 Antibody detection criteria) were performed. More than one serum sample was available from 213 patients (from 2 to 25 samples). At least one serum sample per patient was tested with the whole protocol described in Figure 1, whereas in most cases the follow-up sera drawn were at least partially characterised with, for example, the HEp-
Table 1 Methodological criteria for assignment of autoantibodies

| Autoantibody against | Findings classifying patients as antibody-positive | Usual additional findings |
|----------------------|---------------------------------------------------|---------------------------|
| Centromere           | Centromeric immunofluorescence pattern on HEp-2 cells (308 of 310 were positive) or a CENP-B band in line assay (309 of 310 positive) |
| Topoisomerase I      | At least two of three findings: Scl-70-positive signal in line assay (258 of 260 positive), a band comigrating with a prototype band in IP (all positive), a line of identity in ID with the Scl-70 prototype serum (244 of 260 positive) |
| RNA polymerases      | Characteristic IP pattern comigrating with the pattern of a prototype serum mainly consisting of four bands: la, lb, lla and lllb [58] |
| Fibrillarin          | An IP band (approximately 34 kDa) comigrating with a prototype serum band, plus a nucleolar immunofluorescence pattern on HEp-2 cells |
| To                   | An IP band of approximately 40 kDa plus a nucleolar immunofluorescence pattern on HEp-2 cells; confirmation by immunoblot analysis with recombinant To antigen kindly supplied by Dr M Blüthner, Labor Seelig, Karlsruhe, Germany |
| PM-Scl               | A line of identity in ID with a PM-Scl prototype serum (41 of 42 cases) and/or positive result of ELISA with the synthetic peptide PM-1a [73] (Dr Focke Laboratorien Gmbh, Neuss, Germany) (12 of 13 cases) |
| Ku                   | Two prominent IP bands at about 70 and 80 kDa comigrating with prototype bands |
| U1-RNP               | A positive signal for RNP/Sm in line assay, with or without a positive signal for Sm, plus a typical IP pattern consisting of at least antigen A (about 33 kDa), antigen B/B' (about 28/29 kDa) and antigen C (about 22 kDa) |
| Sm                   | A positive signal for RNP/Sm as well as for Sm in line assay |
| Jo-1                 | A positive signal for Jo-1 in line assay plus a band identical to a Jo-1 prototype band in ID |
| PI-7                 | IP band of about 80 kDa comigrating with prototype band plus a band identical to a PI-7 prototype band in ID |
| OJ                   | Typical triplet band in IP comigrating with prototype bands |
| U11-RNP [74,75]      | An RNP-like IP pattern and coarsely speckled ANA immunofluorescence, without any U11-RNP signals in line assay and ID; U11-RNP specificity detected by C Will and R Lührmann, Marburg, Germany |
| p25/p23 [76,77]      | Doublet IP bands of about 25 and 23 kDa, with the 25 kDa band comigrating with the precipitate of rabbit anti-p25 kindly provided by E Chan, Gainesville, FL, USA |
| SL                   | A band identical to the SL prototype band in ID plus an IP band at about 31 kDa comigrating with the precipitate of the SL reference serum |
| NOR-90               | Doublet IP bands at about 90 kDa comigrating with the precipitate of a NOR-90 reference serum [78] |
| Mitochondrial M2     | AMA M2-positive signal by line assay (40 of 41 positive) and/or AMA typical cytoplasmic immunofluorescence on HEp-2 cells and/or rat kidney sections (27 of 41 positive) |
| Sp100                | Multiple nuclear dot pattern on HEp-2 cells [79] plus Sp100 signal in the line assay HUMAN IMTEC-Liver Line Immunoassay (HUMAN Diagnostics GmbH, Wiesbaden, Germany) |
| Ro52                 | Ro52-positive signal by line assay |
| Ro60                 | Ro60-positive signal by line assay |
| La                   | La-positive signal by line assay |

AMA = antimitochondrial antibodies; ANA = antinuclear antibodies; CENP-B = centromere protein B; ID = immunodiffusion; IP = immunoprecipitation; PM-Scl = polymyositis and scleroderma; RNAP = RNA polymerase; RNP = ribonucleoprotein.
2 cell test. The criteria for classifying sera as positive for autoantibodies are listed in Table 1 together with additional serological results commonly found and helpful to identify the antibodies.

In addition to the autoantibodies defined in Table 1 other circulating autoantibodies detected by at least one of the above-mentioned procedures, either known (for example, anti-histone, anti-dsDNA) or unknown (for example, either unidentified bands in IP or ID or antinuclear or anticytoplasmic antibodies on HEp-2 cells without subsequent identification), were registered. Sera which were negative for ANAs in immunofluorescence on HEp-2 cells but exhibited cytoplasmic fluorescence in that assay and/or a positive signal in any of the other assays were grouped together as ANA-negative. Sera without any positive signal, neither defined nor undefined, in all four assay systems described above were listed as autoantibody-negative.

Statistics
The data were analysed using Microsoft Excel (Microsoft Corp, Redmond, WA, USA) and SPSS version 14.0 software (SPSS, Inc, Chicago, IL, USA) for tabular and graphic representation. Statistical evaluation was performed using contingency table tests with the help of GraphPad Prism version 3.02 software (GraphPad, La Jolla, CA, USA). We calculated OR and 95% CI data. P-values were calculated using Fisher’s exact test. When multiple tests were performed, P-values below 0.005 were recorded without performing strict Bonferroni correction. For most variables, less than 5% of data were missing. Quantitative data (erythrocyte sedimentation rate (ESR), age at disease onset and Rodnan skin score), depending on the presence or absence of different autoantibodies, were analysed using the Mann-Whitney rank-sum test.

Results and discussion
Of the 863 SSc patients studied, 513 (59.4%) were classified as having limited disease and 173 (20.1%) we classified as having diffuse cutaneous disease. Another 108 patients (12.5%) had a scleroderma overlap syndrome, 64 (7.4%) had undifferentiated connective tissue disease with scleroderma features and 5 (0.6%) had systemic sclerosis sine scleroderma.

The frequency of autoantibodies detected in these patients is shown in Table 2. Overall, ANAs were detected in 94.2% of patients. This frequency was similar to data previously published [12,14,15,33,34] in which ANA frequencies reported were between 85% and 99%. Among our patients with ANAs, 86.6% (704 of 813) had autoantibodies known to be highly associated with SSc, and among these latter patients, 96.4% (679 of 704) had antibodies that detected five antigens: centromere, topoisomerase I, PM-Scl, U1-RNP and RNAPs. A coincidence of SSc-associated autoantibodies (Table 3) was rare, being detected in only 1.6% patients (11 of 704). The presence of a SSc-associated antibody without any other autoantibody detectable by the methods used was found at varying frequencies, being highest for anti-PM-Scl (73.8%) and lower for, for example, anti-centromere (33.9%) and anti-fibrillarin (33.3%) (see Table 3). That SSc-associated autoantibodies are largely mutually exclusive is well-known [14,15,35]. Coincidences in individual patients do occur but are rare [33,36,37]. Our study shows that this statement holds true even if all known non-organ-specific, SSc-associated autoantibodies are sought using a rigorous protocol in all patients. On the other hand, additional (mainly not SSc-specific) autoantibodies are common and were detected in about 53% in our patient cohort with SSc-associated antibodies (and in 55.4% of all of our patients). In 14.0% of patients (n = 121), none of the above-mentioned SSc-associated but other (defined or undefined) autoantibodies were found, whereas in 4.4% no autoantibodies at all were

| Autoantibodies                                    | Patients, n (%) |
|---------------------------------------------------|-----------------|
| Positive for antinuclear antibodies               | 813 (94.2)      |
| Antibodies highly associated with SSc or scleroderma overlap syndromes | 704 (81.6)      |
| Anti-centromere                                   | 310 (35.9)      |
| Anti-topoisomerase I                              | 260 (30.1)      |
| Anti-PM-Scl                                       | 42 (4.9)        |
| Anti-U1-RNP                                       | 41 (4.8)        |
| Anti-RNA polymerase                               | 33 (3.8)        |
| Anti-fibrillarin                                  | 12 (1.4)        |
| Anti-To                                           | 2 (0.2)         |
| Anti-Ku                                           | 10 (1.2)        |
| Anti-Jo-1/-Pl-7/-OJ                              | 4 (0.5)         |
| Anti-U11-RNP                                      | 1 (0.1)         |

ANA = antinuclear antibodies; SSc = systemic sclerosis.

### Table 2 Prevalence of autoantibodies in 863 scleroderma patients

| Autoantibodies                        | Patients, n (%) |
|---------------------------------------|-----------------|
| Anti-Ro and/or anti-La                | 206 (23.9)      |
| Anti-Ro52                             | 187 (21.7)      |
| Anti-Ro60                             | 59 (6.8)        |
| Anti-La                               | 16 (1.9)        |
| Anti-mitochondrial M2                 | 41 (4.8)        |
| Anti-p25/p23                          | 28 (3.2)        |
| Anti-NOR-90                           | 6 (0.7)         |
| Anti-SL                               | 9 (1.0)         |
| Anti-Sm                               | 4 (0.5)         |
| Anti-Sp100                            | 4 (0.5)         |
| Other (known or unknown)              | 363 (42.1)      |
| Negative for all highly SSc-associated antibodies | 159 (18.4) |
| Negative for antinuclear antibodies   | 50 (5.8)        |
| Autoantibody-negative by all criteria used | 38 (4.4)       |
| Antibodies     | ACA  | ATA  | Anti-PM-Scl | Anti-U1-RNAP | Anti-fibrillarin | Anti-To | Anti-Ku | Anti-Jo-1/Pl-7/OJ | Anti-U11-RNAP | Anti-Ro52 | Anti-Ro60 | Anti-La | AMA | Anti-NOR-90 | Anti-SL | Anti-Sm | Anti-Sp100 | Other |
|----------------|------|------|-------------|--------------|-----------------|---------|---------|-----------------|--------------|------------|-----------|---------|-----|------------|--------|--------|-----------|-------|
| ACA            | 1    | 0    | 1           | 0            | 0               | 0       | 0       | 0               | 0            | 92         | 11        | 31      | 28  | 4          | 2      | 3      | 144       |
| ATA            | 1    | 2    | 0           | 0            | 4               | 0       | 0       | 36              | 2            | 26         | 26        | 2        | 0  | 1          | 4      | 1      | 0         | 77    |
| Anti-PM-Scl    | 0    | 0    | 0           | 1            | 0               | 0       | 6       | 20              | 0            | 0          | 0         | 0       | 0  | 0          | 0      | 0      | 4         |
| Anti-U1-RNAP   | 1    | 0    | 0           | 0            | 0               | 0       | 11      | 6               | 1            | 2          | 1         | 0       | 1  | 4          | 0      | 4      | 11        |
| Anti-RNAP      | 0    | 0    | 0           | 0            | 0               | 0       | 5       | 1               | 1            | 1          | 0         | 0       | 1  | 0          | 0      | 5      | 0         |
| Anti-fibrillarin | 0     | 0    | 0           | 0            | 0               | 0       | 0       | 0               | 1            | 0          | 0         | 0       | 0  | 8          |        |        |           |
| Anti-To        | 0    | 0    | 0           | 1            | 1               | 0       | 0       | 0               | 0            | 0          | 0         | 0       | 0  | 2          |        |        |           |
| Anti-Ku        | 0    | 0    | 2           | 2            | 0               | 0       | 0       | 1               | 0            | 0          | 0         | 0       | 0  | 2          |        |        |           |
| Anti-Jo-1/Pl-7/OJ | 0    | 3    | 0           | 0            | 0               | 0       | 0       | 0               | 0            | 0          | 0         | 0       | 0  | 1          |        |        |           |
| Anti-U11-RNAP  | 0    | 0    | 0           | 0            | 0               | 0       | 0       | 0               | 0            | 0          | 0         | 0       | 0  | 0          |        |        |           |
| Anti-Ro52      | 41   | 15   | 14          | 11            | 2               | 5       | 2       | 2               | 2            | 97         |           |         |     |            |        |        |           |
| Anti-Ro60      | 14   | 6    | 0           | 0             | 0               | 1       | 1       | 1               | 33           |            |           |         |     |            |        |        |           |
| Anti-La        | 1    | 0    | 0           | 0             | 1               | 0       |         |                  |               |            |           |         |     |            |        |        |           |
| AMA            | 2    | 0    | 1           | 1             | 2               | 11      |         |                  |               |            |           |         |     |            |        |        |           |
| Anti-p25/p23   | 1    | 1    | 0           | 1             | 1               | 18      | 0       | 1               | 4            |            |           |         |     |            |        |        |           |
| Anti-NOR-90    | 0    | 1    | 0           | 4             |                |         |         |                  |               |            |           |         |     |            |        |        |           |
| Anti-SL        | 0    | 0    | 3           |                |                |         |         |                  |               |            |           |         |     |            |        |        |           |
| Anti-Sm        | 0    | 0    | 0           |                |                |         |         |                  |               |            |           |         |     |            |        |        |           |
| Anti-Sp100     | 2    |      |             |                |                |         |         |                  |               |            |           |         |     |            |        |        |           |
| Other          |      |      |             |                |                |         |         |                  |               |            |           |         |     |            |        |        | 79        |
| Isolateda      | 104  | 153  | 31          | 19            | 23              | 4       | 0       | 4               | 1            | 1          | 1         | 2       | 1  | 0          | 0      | 0      | 1         | 4    |
| Totalb         | 310  | 260  | 42          | 41            | 33              | 12      | 2       | 10              | 4            | 1         | 187       | 59      | 16  | 41         | 28     | 6      | 9         | 4    |

*Number of patients with co-occurrences of autoantibodies. *Isolated: presence without coincidence of any other autoantibody by all detection methods used. Total number of individuals with the respective autoantibody; these numbers mostly are smaller than the sum of all co-occurrences plus the ‘isolated’ individuals listed because of some triple, quadruple and higher-order coincidences. ACA = anti-centromere antibodies; ATA = antitopoisomerase I antibodies; RNAP = RNA polymerase; RNP = ribonucleoprotein.
detected by the methods used. Defined autoantibodies not regarded as SSc-specific, such as anti-Ro/La, anti-NOR-90 or AMAs rarely occurred without the evidence of SSc-associated autoantibodies (Table 3). Antibodies to p25/p23 were detected exclusively in conjunction with ACA.

From 213 patients, more than one serum sample was available (from 2 to 25 samples). In the majority (86.4%) of cases, the results of follow-up testing remained essentially the same and differed in ANA titre by up to only two titre steps. In 11.3% (24 patients), ANA titre changes exceeded two steps (up to eight steps), in two cases ANAs turned negative, in one case the ANA pattern changed from finely granular to nucleolar and in only two cases new, additional typical SSc autoantibodies emerged.

The detection of antibodies in different disease subsets is shown in Table 4. It is obvious that ACA and ATA are not exclusive to either the limited or the diffuse subset. In patients with overlap syndrome, anti-U1-RNP, anti-PM-Scl and anti-synthetase antibodies are characteristic.

The correlation of demographic features or signs and symptoms of SSc with the presence or absence of defined autoantibodies was investigated by contingency table analysis. The frequencies of these features and their positive or negative correlations with specific autoantibodies are listed in Table 5. For the purpose of clarity, only those comparisons that led to P-values below 0.05 derived by Fisher's exact test are shown. Significance was calculated without correction of P-values for multiple comparisons, because not all variables used were independent; however, we are aware of the fact that some of the weak associations listed in Table 5 might have arisen by chance due to the high number of comparisons made. Therefore, we focused on those differences calculated that were highly significant (P < 0.005; OR printed in bold in Table 5).

Patients with ACA represented 35.9% of all SSc patients and 38.1% of ANA-positive SSc patients. In accordance with previous reports [8,9,12,15,33,36,38,39], these patients were less often male, were older at disease onset and had a more limited extension of cutaneous involvement, as documented by a much lower OR for a Rodnan skin score (RSS) above 10 (Table 5) and by a very significantly lower mean RSS (Table 6). They had less involvement of internal organs (pulmonary fibrosis, cardiac, musculoskeletal and oral involvement), with the exception of pulmonary hypertension. An association of ACA with pulmonary hypertension has been observed in several previous reports [2,12,33,40], but not all of them [13,36,38,39]. Digital ulcers in our patients with

### Table 4 Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients

| Antibodies | Limited (N = 513) | Diffuse (N = 173) | Overlap (N = 108) | Undifferentiated (N = 64) |
|------------|-----------------|-----------------|-----------------|-----------------|
| ACA        | 253 (49.3)      | 5.00 (P < 0.0001) | 12 (6.9) | 16 (14.8) | 28 (43.8) |
| ATA        | 141 (27.5)      | 98 (56.6)       | 4.26 (P < 0.0001) | 11 (10.2) | 141 (27.5) |
| Anti-RNAP  | 14 (2.7)        | 14 (8.1)        | 3.11 (P = 0.0029) | 2 (1.9) | 14 (2.7) |
| Anti-U1-RNP| 7 (1.4)         | 0 (0.0)         | 31 (28.7)       | 30.00 (P < 0.0001) | 2 (1.9) |
| Anti-PM-Scl| 16 (3.1)        | 2 (1.2)         | 22 (20.4)       | 9.40 (P < 0.0001) | 2 (1.9) |
| Anti-fibrillarin | 3 (0.6) | 8 (4.6) | 8.32 (P = 0.0005) | 1 (0.9) | 3 (0.6) |
| Anti-To    | 1 (0.2)         | 0 (0.0)         | 1 (0.9)         | 0 (0.0) | 1 (0.2) |
| Anti-Jo-1/Pl-7/OJ | 0 (0.0) | 0 (0.0) | 3 (3.7) | 65.07 (P = 0.0002) | 0 (0.0) |
| Anti-U11-RNP| 0 (0.0)        | 1 (0.6)         | 0 (0.0)         | 0 (0.0) | 0 (0.0) |
| Anti-Ku    | 5 (1.0)         | 1 (0.6)         | 3 (2.8)         | 1 (1.6) | 5 (1.0) |
| Anti-SL    | 5 (1.0)         | 3 (1.7)         | 1 (0.9)         | 0 (0.0) | 5 (1.0) |
| Anti-Sm    | 0 (0.0)         | 0 (0.0)         | 3 (2.8)         | 21.54 (P = 0.0069) | 3 (0.0) |
| Anti-NOR-90| 5 (1.0)         | 0 (0.0)         | 1 (0.9)         | 0 (0.0) | 5 (1.0) |
| AMA        | 28 (5.5)        | 4 (2.3)         | 4 (3.7)         | 5 (7.8) | 28 (5.5) |
| Anti-Sp100 | 3 (0.6)         | 0 (0.0)         | 0 (0.0)         | 1 (1.6) | 3 (0.6) |
| Anti-Ro52  | 125 (24.4)      | 20 (11.6)       | 27 (25.0)       | 15 (23.4) | 125 (24.4) |
| Anti-Ro60  | 28 (5.4)        | 14 (8.1)        | 13 (12.0)       | 21.11 (P = 0.0382) | 4 (6.3) |
| Anti-La    | 9 (1.8)         | 3 (1.7)         | 1 (0.9)         | 3 (4.7) | 9 (1.8) |
| Anti-p25/p23| 24 (4.5)       | 0 (0.0)         | 2 (1.9)         | 2 (3.1) | 24 (4.5) |
| Other      | 209 (40.7)      | 74 (42.8)       | 44 (40.7)       | 34 (53.1) | 209 (40.7) |
| ANA-negative| 36 (6.2)      | 6 (3.5)         | 5 (4.6)         | 7 (10.9) | 36 (6.2) |

ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase.

*OR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005 are printed in bold.*
Table 5 Correlations of clinical features with SSc associated autoantibodies

| Feature                                      | ACA (310) | ATA (260) | Anti-PM-Scl (42) | Anti-U1-RNP (41) | Anti-RNA-P (33) | Anti-Fibrillarin (12) | Anti-Ku (10) | Anti-Ro52 (187) | Anti-Ro60 (59) | Anti-La (16) | AMA (41) | Anti-p25/23 (28) | ANA-negative (50) | no SSc associated ab’s (161) |
|----------------------------------------------|-----------|-----------|------------------|------------------|-----------------|----------------------|---------------|----------------|----------------|--------------|----------|----------------|----------------|------------------|
| Male sex                                     | 17        | 64        | 0.19 (0.11 to 0.32) | 2.02 (1.4 to 2.9) | 6               | 9                    | 8             | 4              | 2              | 23          | 0.62 (0.38 to 0.99) | 12              | 2                | 1              | 1              | 10          | 1.90 (1.26 to 2.86) | p = 0.0035 |
| Age at disease onset < 50 y                  | 115       | 135       | 0.57 (0.43 to 0.77) | 1.39 (1.02 to 1.88) | 22              | 29                   | 13            | 8              | 4              | 77          | 0.0097 | 31              | 10              | 20               | 8              | 18             | 73          |
| Rodnan skin score > 10                       | 58        | 132       | 0.27 (0.19 to 0.38) | 3.10 (2.24 to 4.27) | 14              | 9                    | 18            | 7              | 1              | 58          | 0.0029 | 23              | 6               | 10               | 11             | 14             | 56          |
| Raynaud’s phenomenon                         | 301       | 252       | 2.26 (1.07 to 4.7)  | 0.00394          | 37              | 41                   | 32            | 12             | 10             | 184         | 3.96 (1.2 to 12.94) | 0.0133 | 58              | 16             | 41              | 28          | 43          | 0.29 (0.12 to 0.70) | p = 0.0104 |
| Pulmonary hypertension                       | 57        | 36        | 1.58 (1.08 to 2.32) | 0.02088          | 2               | 9                    | 4             | 1              | 0              | 31          | 0.0076 | 14              | 2               | 2               | 2              | 2              | 7           | 48          | 0.26 (0.09 to 0.76) | p = 0.0024 |
| Pulmonary fibrosis                           | 39        | 41        | 0.18 (0.12 to 0.26) | 4.76 (3.48 to 6.5) | 16              | 11                   | 7             | 2              | 6              | 69          | 0.0040 | 30              | 2.20 (1.29 to 3.75) | p = 0.001 | 9              | 6             | 4              | 11          | 55          |
| Lung restrictive defect                       | 41        | 104       | 0.31 (0.21 to 0.45) | 2.96 (2.14 to 4.09) | 9               | 7                    | 8             | 3              | 4              | 45          | 0.0080 | 19              | 4               | 8               | 4              | 10             | 34          |
| Esophageal involvement                       | 198       | 175       | 1.39 (1.02 to 1.89) | 0.29 (0.152 to 0.56) | 29              | 20                   | 7             | 6              | 120            | 30         | 0.0101 | 39              | 13             | 24              | 21             | 27             | 87          | 0.67 (0.47 to 0.94) | p = 0.0243 |
| Proteinuria                                  | 23        | 34        | 0.56 (0.34 to 0.92) | 0.00207          | 4               | 4                    | 4             | 1              | 1              | 15          | 0.0001 | 9               | 2               | 3              | 1              | 5              | 19          |
| Clinical Feature                | N   | OR (95% CI) | p     |
|--------------------------------|-----|-------------|-------|
| Cardiac involvement            | 114 (13.2%) | 0.51 (0.32 to 0.81) | 0.0033 |
|                                | 45  | 1.62 (1.08 to 2.44) | 0.0216 |
| Musculoskeletal involvement    | 421/852 (49.4%) | 0.64 (0.48 to 0.85) | 0.0022 |
|                                | 130 | 2.49 (1.25 to 4.96) | 0.009  |
| Synovitis                      | 157/837 (18.8%) | 0.43 (0.29 to 0.65) | P < 0.0001 |
|                                | 35  | 2.27 (1.14 to 4.53) | 0.0326 |
| Joint contractures             | 253/840 (30.1%) | 0.36 (0.25 to 0.50) | P < 0.0001 |
|                                | 107 | 2.26 (1.65 to 3.08) | P < 0.0001 |
| Tendon friction rubs           | 88/840 (10.5%) | 0.30 (0.16 to 0.53) | P < 0.0001 |
|                                | 32  | 2.10 (1.53 to 2.86) | 0.0009 |
| CK elevation                   | 74/835 (8.9%) | 0.37 (0.21 to 0.68) | P < 0.0001 |
|                                | 14  | 2.60 (1.03 to 6.55) | 0.0485 |
| Sicca syndrome                 | 366/858 (42.7%) | 1.44 (1.19 to 1.81) | P = 0.0119 |
|                                | 150 | 1.98 (1.44 to 2.71) | 0.009  |
| Mouth involvement              | 223/829 (26.9%) | 0.61 (0.44 to 0.85) | P = 0.0034 |
|                                | 90  | 2.15 (1.33 to 3.43) | P = 0.0001 |
| ESR > 25 mm/h                  | 199/741 (26.9%) | 0.70 (0.49 to 0.99) | P = 0.046 |
|                                | 58  | 1.55 (1.10 to 2.19) | P = 0.046 |

ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; CK, creatine kinase; ESR, erythrocyte sedimentation rate; RNAP = RNA polymerase; RNP = ribonucleoprotein; SSc, systemic sclerosis. Dichotomous variables are expressed as raw numbers, OR (95% CI) and p values.
ACA were less common compared to American patients [2] and more similar to European [9,12,38] and Japanese patients [34]. Nevertheless, the presence of ACA does not by any means preclude digital ulcers. To date no marker constellation allows the identification of patients prone to this complication [41-43]. ACAs are frequently associated with other antibodies, such as anti-Ro [44-46], anti-mitochondrial (M2) [15,44,47,48] and anti-p25/p23 [31,49,50] antibodies. These associations were also noted in previous reports [2,14,33,34,36,40,54-60]. In addition, we found creatine kinase (CK) elevation to be more frequent in patients with anti-RNAP antibodies (Tables 5 and 6) as previously observed [2,14,33,34,36,40,54-60]. Furthermore, renal involvement was not more prevalent in this subgroup, a finding reported by most other researchers [8,9,14,15,33,36,51,52] but not all of them [2,34].

The frequency of RNAP antibodies in our cohort was 3.8%, which is at the lower end of the frequency range reported by others, namely, 10% to 25% in North America [33,52-55], 4% to 31.5% in Europe [14,16,33,35,56-59] and 5% to 11% in Japan [34,36,60]. This may have several reasons: (1) Our cohort is composed of a broad spectrum of SSc patients, including patients with milder forms and with overlap or undifferentiated subotypes of the disease, (2) regional differences due to genetic background and/or environmental influences and (3) different techniques used to ascertain the presence of RNAP antibodies. A high mean RSS, reflecting diffuse skin involvement, was evident for patients with anti-RNAP antibodies (Tables 5 and 6) as previously observed [2,14,33,34,36,40,54-60]. In addition, we found creatine kinase (CK) elevation to be more frequently associated with the presence of anti-RNAP antibodies. This has not been noted before; association with muscular involvement has been found to be nonsignificant [14,34,40,53,54] or even inverse [2,36,55] in previous publications. Our result in this study therefore might be a chance finding due to multiple comparisons. We did not find any significant positive association of RNAP antibodies, or any autoantibody evaluated in this study, with renal involvement. In the German Network for Systemic Scleroderma Registry, ‘renal involvement’ is defined as renal insufficiency in the form of decreased creatinine clearance and/or proteinuria, as well as a consequence of acute renal crisis. The registry did not include renal crisis as a separate item at that time, which may underestimate the possible correlation of antibodies with renal crisis [18]. Within our network, the frequency of renal crisis currently does not exceed 2% to 3% per year (Hunzelmann N, unpublished observation). The prevalence of renal crisis among patients with RNAP antibodies, or any autoantibody evaluated in this study, was not more prevalent in this subgroup, a finding reported by most other researchers [8,9,14,15,33,36,51,52] but not all of them [2,34].

Table 6 Correlations of clinical features with systemic sclerosis-associated autoantibodies

| Quantitative traits          | Clinical data                                      | P     |
|------------------------------|----------------------------------------------------|-------|
| Age at disease onset         | n Mean ± SD (years)                               |       |
| Total                        | 781 47.7 (14.2)                                    |       |
| Anti-centromere              | 273 51.3 (12.5)                                    | < 0.0001|
| Anti-topoisomerase I         | 238 46.0 (14.0)                                    | 0.0076 |
| Anti-fibrillarin             | 12 38.8 (16.0)                                     | 0.0404 |
| Anti-U1-RNP                  | 39 38.2 (15.0)                                     | < 0.0001|
| Anti-La                      | 15 37.9 (18.1)                                     | 0.0431 |
| Autoantibody-negative        | 36 52.9 (14.7)                                     | 0.0205 |
| Rodnan skin score            | n Mean score ± SD                                |       |
| Total                        | 750 10.2 (9.4)                                     |       |
| Anti-centromere              | 275 6.4 (6.0)                                      | < 0.0001|
| Anti-topoisomerase I         | 227 14.1 (9.7)                                     | < 0.0001|
| Anti-RNA polymerase          | 27 15.7 (11.7)                                     | 0.0091 |
| Anti-fibrillarin             | 10 21.2 (15.0)                                     | 0.0108 |
| Anti-U1-RNP                  | 35 6.9 (9.2)                                       | 0.0053 |
| Erythrocyte sedimentation rate| n Mean ± SD (mm/hour)                             |       |
| Total                        | 741 19.46 (16.7)                                  |       |
| Anti-topoisomerase I         | 227 22.95 (19.1)                                  | 0.0002 |
| Anti-Pm-Scl                  | 36 12.19 (9.4)                                     | 0.0014 |
| Anti-Ro52                    | 167 220.5 (18.8)                                  | 0.0374 |
| Anti-Ro60                    | 53 28.47 (19.6)                                   | < 0.0001|
| Anti-La                      | 16 28.56 (20.1)                                   | 0.0447 |

PM-Scl = polymyositis and scleroderma; RNP = ribonucleoprotein; SSc, systemic sclerosis. *P*-value calculated by Mann-Whitney rank-sum test for comparison of antibody-positive vs antibody-negative patients.
methodological differences and/or the central European background of the patients. Ethnic heterogeneity with a higher frequency of anti-fibrillarin antibodies in black patients has been described previously [2,13,40,61-63]. Our findings of a lower age at disease onset and a higher prevalence of musculoskeletal involvement (Tables 5 and 6) are in line with most previous results [2,36,61,63].

The frequency of PM-Scl antibodies (4.9%) detected in our cohort is in accord with previously published studies in which frequencies between 2% and 6% were noted for SSc patients [1-3,17,33]. These antibodies are most well-known as being typical in patients with dermatomyositis-scleroderma overlap syndrome [1,3]. Accordingly, CK elevation was highly associated with anti-PM-Scl in our cohort. On the other hand, these patients were markedly less likely to have oesophageal involvement (Table 5) and had a low mean ESR (Tables 5 and 6). We found elevated ESR levels in an earlier series of SSc patients with anti-PM-Scl antibodies [32], but others, to the best of our knowledge, did not. (Patients with anti-PM-Scl have rarely been analysed in the large SSc series reported previously.) Therefore, this finding has to be reproduced by independent work in the future. That these patients have a relatively benign prognosis has been mentioned several times before [64-66]. Accordingly, 31% of our patients with anti-PM-Scl antibodies were devoid of any internal organ involvement, compared with 13% of the patients without anti-PM-Scl ($P = 0.0023$, data not shown).

Antibodies to Ku, when found in SSc patients, are often associated with scleroderma overlap syndrome and with muscular involvement [17,36]. Accordingly, we registered a high OR, but with low significance because of the relatively low patient number, for CK elevation associated with anti-Ku antibody (Table 5). The complete absence of ACA and the occasional presence of ATA described in a large previous study that focused on ACA-positive SSc patients [44,45,69,70], were associated with sicca syndrome. This association was only marginally significant; in fact, the antibodies with the most prominent association with the sicca complex were, as mentioned above, anti-p25/p23 antibodies. Anti-Ro and/or anti-La antibodies showed a particularly high correlation with elevated ESR (Tables 5 and 6). An unexpectedly strong association of anti-Ro60 with pulmonary fibrosis (Table 5) was mainly secondary to the relatively high co-occurrence of this antibody with ATA (see Table 3).

No highly significant differences for any of the autoantibody-defined subgroups could be found for gastric, intestinal or renal involvement, including hypertension and reduced renal function. Furthermore, no significant differences dependent on antibodies against aminoacyl-transfer RNA synthetases, To, Sm, SL or NOR-90 were detected, probably because of the low numbers of patients positive for these antibodies. Patients without highly SSc-associated antibodies were more often male and less frequently had Raynaud’s phenomenon.

**Conclusions**

The occurrence of SSc-related autoantibodies has never been analysed in such detail in a cohort as large as this one. We have shown that five antigens appear to be sufficient to detect more than 95% of the known SSc-associated autoantibody responses in ANA-positive SSc patients. In more than half of patients with a SSc-associated antibody, other nuclear autoantibodies were detected and a considerable patient group (around 40%) still displayed uncharacterised ANAs of as yet unknown significance.

To the best of our knowledge, this is the largest comprehensive analysis of the presence of SSc-associated as well as other non-organ-specific autoantibodies in SSc patients that was performed in a single central laboratory and demonstrates the complexity and heterogeneity
of the autoimmune response underlying the pathogenesis of this still enigmatic disease.

Acknowledgements
The expert technical assistance of Marie-Claire Vondegracht and Rita Bernstein is gratefully acknowledged. Furthermore, we are indebted to Dr M Bültner, Laboratory Prof Seelig, Karlsruhe, Germany, for confirming the anti-To antibodies; to Dr C Will and Professor R Lührmann, Marburg, Germany, for identification of the anti-U1 RNP antibodies; and to Dr EK Chan, Gainesville, FL, USA, Prof B Liedvogel, Daeict, Freiburg, Germany, and Dr W Schumlinger, Euroimmun, Lübeck, Germany, for supplying rabbit anti-sera to p25/p23, recombinant P-Ag-Sd antigens, and investigational anti-fibrillarin ELISA kits, respectively. We also thank A Fehr and B Damm for data acquisition and management and Hildegard Christ and PD Dr Martin Hellmich for statistical advice. This study was supported by the German Federal Ministry of Education and Research (BMBF) (grants 01GM0310 and 01GM0630).

Author details
1Laboratory at Rheumaklinik Aachen, Hauptstrasse 21, Aachen, D-52066, Germany. 2Department of Dermatology and Venerology, University of Cologne, Kerpener Strasse 62, Cologne, D-50937, Germany. 3Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Humboldt University, Charitéplatz 1, Berlin, D-10117, Germany. 4Clinical Research Unit for Rheumatology, University Medical Center Freiburg, Breisacher Strasse 66, Freiburg, D-79106, Germany. 5Department of Dermatology, Dresden University Hospital, Fetscherstrasse 74, Dresden, D-01307, Germany. 6Department of Internal Medicine II, University of Giessen, Klinikstrasse 33, Giessen, D-35392, Germany. 7Clinic for Rheumatology, Schoneckhalde 13, Bad Sackingen, D-79713, Germany. 8Reha-Rheinfelden, Salinenstrasse 98, Rheinfelden, CH-3410, Switzerland. 9Department of Dermatology, Venerology and Allergology, Charité Universitätsmedizin, Humboldt University, Charitéplatz 1, Berlin, D-10117, Germany. 10Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, D-69120, Germany. 11Department of Dermatology and Allergology, Technical University of Munich, Biedersteiner Strasse 29, Munich, D-81669, Germany. 12Department of Rheumatology and Clinical Immunology, Kerkhoff Clinic, Justus-Liebig University, Benekestrasse 2, Bad Nauheim, D-66321, Germany. 13Department of Rheumatology, Heinrich-Heine-University, Moorenstrasse 5, Dusseldorf, D-40225, Germany. 14Department of Dermatology, University of Munster, Von-Esmarch-Straße 58, Munster, D-48149, Germany. 15Center of Rheumatology of Brandenburg, Johanner Hospital in Fläming, Johanniterstrasse 1, Treuenbrietzen, D-14009, Germany. 16Department of Dermatology and Allergology, University of Ulm, Maenwegen 12, Ulm, D-89081, Germany. 17Department of Rheumatology, Acura Hospital, Rotenbachtalstrasse 5, Baden-Baden, D-76530, Germany. 18Department of Dermatology, Venerology and Allergology, University of Leipzig, Philipp-Rosenthal-Strasse 23, Leipzig, D-04103, Germany. 19Department of Dermatology, University Hospital Erlangen, Ullmenweg 18, Erlangen, D-91054, Germany. 20Department of Dermatology and Allergology, Helios Klinikum, Heussinerstrasse 40, Wuppertal, D-42283, Germany. 21Department of Dermatology, Johannes-Wesling-Klinik, Hans-Nolte-Strasse 1, Minden, D-32429, Germany. 22Medical Clinic I, Hospital Cologne-Cronenbourg, Ostheimer Strasse 200, Cologne, D-51109, Germany. 23Medical Clinic 6, Marien-Hospital, Warheimer Strasse 167a, Dusseldorf, D-47053, Germany. 24Department of Dermatology, Venerology and Allergology, University of Würzburg, Josef-Schneider-Strasse 2, Würzburg, D-97080, Germany. 25Department of Dermatology, Venerology and Allergology, University of York, D-37075, Germany. 26Hospital for Pediatric and Adolescent Rheumatology, Dehnhaide 120, Hamburg Elbrik, D-22081, Germany. 27Rheumaklinik Aachen, Bultscheider Markt 24, Aachen, D-52066, Germany.

**Authors’ contributions**
RM designed the study, performed the serological analyses, had full access to all of the data in the study, analysed the data, takes responsibility for the integrity of the data and the accuracy of the data analysis, interpreted the data, and drafted the manuscript. EC designed the study, was responsible for overall project management, enrolled patients for the network, and contributed data from one participating centre. TK designed the study and was responsible for overall project management. PM, GR, MM, FR, MB, MW, NB, RH, AK, CS, AJ, CP, CF, MS, PL, RS, ESL, CS and IF enrolled patients for the network and contributed the data from the participating centres. IM and UML were responsible for overall project management, enrolled patients for the network and contributed the data from the participating centres. NH interpreted the data and drafted the manuscript, was responsible for overall project management and designed the study. All authors critically revised the manuscript and read and approved the final manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

**References**
1. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. *Curr Opin Rheumatol* 2004, 16:723-732.
2. Steen VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum* 2005, 35:35-42.
3. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. *Curr Opin Rheumatol* 2007, 19:580-591.
4. Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D’Angelo WAD, Fries JF, LeRoy EC, Kinner A8, Mackenzie AH, McShane DJ, Myers AR, Sharp GC, the Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980, 23:581-590.
5. LeRoy EC, Medsger TA. JR. Criteria for the classification of early systemic sclerosis. *J Rheumatol* 2001, 28:1573-1576.
6. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grotzicky T, Raymond Y, Senécal JL. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum* 2008, 58:3902-3912.
7. Elich Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. *Arthritis Rheum* 2001, 44:376-383.
8. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. *Arthritis Rheum* 1998, 41:196-203.
9. Ferri C, Valentinis G, Coazi F, Sebastiani M, Michelassi C, La Montagna G, Bulla A, Cazzato M, Tirri E, Stortino F, Gugliotti D, Cuomo G, Rosada M, Bombardett S, Todesco S, Tirri G. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. *Medicine* 2002, 81:159-173.
10. Sciascia-Lonzetti L, Joyal F, Raynaud JP, Roussin A, Rich E, Goulet JR, Raymond Y, Senécal JL. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. *Medicine (Baltimore)* 2002, 81:154-167.
11. Mayes MD, Lacey JV Jr, Beebe-O’Merrill J, Gillies BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. *Arthritis Rheum* 2003, 48:2246-2255.
12. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Koval-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matsuoco-Cennic M, EUSTAR. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. *Ann Rheum Dis* 2007, 66:754-763.
13. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leard K, Smith EA, LeRoy EC, Fritzler MJ. Autoantibodies to fibrillarin in systemic sclerosis.
Scleroderma: an immunogenetic, serologic, and clinical analysis. *Arthritis Rheum* 1996, 39:1151-1160.

14. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM: Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. *Br J Rheumatol* 1998, 37:15-20.

15. Jacobsen S, Halberg P, Ullman S, van Veenooij WJ, Haier-Madsen M, Wilk A, Petersen J: Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. *Br J Rheumatol* 1998, 37:39-45.

16. Hesselstrand R, Schjei A, Shen GQ, Wilk A, Akesson A: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. *Arthritis Rheum* (Oxford) 2003, 42:534-540.

17. Rozman B, Cunicik S, Sodin-Semrl S, Cizjak L, Vargic D, Distler O, Hudcik S, Aringer M, Steiner G, Matusic-Cerinic M, Guiducic S, Stamenkovic B, Stankovic A: Kveider T: Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. *Ann Rheum Dis* 2008, 67:1282-1286.

18. Hunzelmann N, Genth E, Krieg T, Lehmanner W, Melchers I, Meurer M, Monizadeh P, Muller-Ladner U, Pfeiffer C, Riemarkasten G, Schulze-Lohoff E, Sunderkötter C, Weber M, German Network for Systemic Scleroderma Centers: High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. *Arthritis Res Ther* 2009, 11:R30.

19. LeRoy EC, Black C, Fleischmajer R, Jaklonska S, Krieg T, Medsger TA Jr, Rowell N, Wolffman F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol* 1988, 15:202-205.

20. Bennett RM: Scleroderma overlap syndromes. *Rheum Dis Clin North Am* 1990, 16:185-198.

21. Pope JE: Scleroderma overlap syndromes. *Curr Opin Rheumatol* 2002, 14:704-710.

22. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. *Arthritis Rheum* 2000, 43:444-451.

23. Giordano AE, Dore CJ, Dunphy J, Betteridge Z, McHugh NJ, Maddison PJ: Antinuclear antibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. *J Rheumatol* 2011, 38:702-705.

24. Targoff IN: Frequency and clinical associations of anti-chromo antibodies associated with anti-centromere antibodies. *J Autoimmun* 2002, 19:166-174.

25. Muro Y, Yamada T, Iwai T, Sugimoto K: Epitope analysis of chromo antigen and clinical features in a subset of patients with anti-centromere antibodies. *Arthritis Rheum* 2003, 49:117-143.

26. Hanke K, Dahnhart C, Brückner CS, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Heipe F, Burmester GR, Riemarkasten G: Antigen recognition of autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic sclerosis. *J Mol Med (Berl)* 1998, 76:54-60.

27. De Strooper W, Mestdagh P, Meuwissen M, Schellekens H, Van den Steen P, Tjalsma H: Immune response to the centromere protein p25B in autoantibodies and clinical associations with systemic sclerosis. *J Autoimmun* 2008, 31:465-473.

28. Harvey GR, Black CM, Maddison PJ, McHugh NJ: Characterization of antinuclear antibody reactivity in patients with systemic sclerosis and their relatives. *J Rheumatol* 1997, 24:477-484.

29. Hirakata M, Suwa A, Takada T, Sato N, Nagai S, Genth E, Song YW, Mimori T, Targoff IN: Clinical and immunogenetic features of patients with autoantibodies to asparaginyl transfer RNA synthetase. *Arthritis Rheum* 2007, 56:1295-1303.

30. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y: Clinical, serological and genotype features in a monocentric cohort. *Arthritis Rheum* 2013, 65:725-734.

31. Hamilton JA, Steen VD, Medsger TA Jr, Black CM, Brázdil J, Davis JF, Estrella P, Hiepe F, Medsger TA Jr, Paasch U: Clinical, serological and genotypic features of patients with anti-centromere antibodies. *J Rheumatol* 2006, 33:1409-1415.

32. Miyawaki S, Nishiyama S, Yoshinaga Y, Black CM, Medsger TA Jr, Brázidil J: Clinical, serological and genotypic features of patients with anti-centromere antibodies. *J Rheumatol* 2009, 36:1409-1415.

33. Follin E, Bünger MD, Salloum M, Salloum M, Zelenkofske L, Youssef A, Brázdil J: Clinical and immunogenetic associations of anti-centromere antibodies. *Arthritis Rheum* 2011, 63:704-710.

34. Hamaguchi Y, Hasegawa M, Fujimoto M, Komura K, Nagai S, Genth E, Song YW, Mimori T, Sato S: The clinical relevance of serum anticentromere antibodies in Japanese patients with systemic sclerosis. *Br J Dermatol* 2008, 158:487-495.

35. Fanning GW, Welsh N, Bunn C, du Bois RM, Black CM: HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. *Br J Rheumatol* 1998, 37:201-207.

36. Kuwana M, Kabasumi J, Ogawa F, Takekara K, Sato S: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. *Arthritis Rheum* 1994, 37:75-83.

37. Dick T, Mierau R, Bartz-Bazella P, Alavi M, Stoyanova-Scholz M, Kindler J, Gentz E: Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis. *Ann Rheum Dis* 2002, 61:121-127.

38. Hanke K, Becker MO, Brueckner CS, Meyer W, Jansen A, Schluormalber W, Heipe F, Burmester GR, Riemarkasten G: Antigen recognition of autoantibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. *J Rheumatol* 2011, 38:702-705.

39. Follin E, Bünger MD, Salloum M, Salloum M, Zelenkofske L, Youssef A, Brázdil J: Clinical, serological and genotypic features of patients with anti-centromere antibodies. *J Rheumatol* 2006, 33:1409-1415.
1989, 33:129-133.
58. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ: Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. *Clin Exp Immunol* 2000, 117:395-402.
59. Airo P, Cenibelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F: Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. *J Rheumatol* 2011, 38:1329-1334.
60. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mmoni T, Muro Y, Yazawa N, Sato S, Takehara K, Kutsuna M: Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. *Rheumatology (Oxford)* 2009, 48:1570-1574.
61. Tormey VL, Bunn CC, Denton CP, Black CM: Anti-fibrillarin antibodies in systemic sclerosis. *Rheumatology (Oxford)* 2001, 40:1157-1162.
62. Reveille JD, Frischbach M, McNeary T, Friedman AW, Aguilar MB, Lisse J, Fritzer MJ, Ahn C, Amett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. *Semin Arthritis Rheum* 2001, 30:332-346.
63. Aggarwal R, Lucas M, Fertig N, Odiss CV, Medsger TA Jr: Anti-U3 RNP autoantibodies in systemic sclerosis. *Arthritis Rheum* 2009, 60:1112-1118.
64. Odiss CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. *Arthritis Rheum* 2003, 49:1211-1217.
65. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, So AK, Walport MJ: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. *Medicine (Baltimore)* 1992, 71:327-336.
66. Vanderheyst M, Ocmant A, Sordet C, Humbel RL, Goetz J, Roufosse F, Cogan E, Sibilia J: Anti-PM/Scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. *Clin Exp Rheumatol* 2006, 24:129-133.
67. Targoff IN: Heterochromatin immunity in polymyositis/dermatomyositis. *J Invest Dermatol* 1993, 100:1165-1183.
68. Katano K, Kawana M, Koni I, Sugai S, Muro Y: Clinical and laboratory features of anticientromere antibody positive primary Sjögren’s syndrome. *J Rheumatol* 2001, 28:2218-2244.
69. Osial TA Jr, Whiteside TL, Buckingham RB, Singh G, Barnes EL, Pierce JM, Rodnan GP: Clinical and serological study of Sjögren’s syndrome in patients with progressive systemic sclerosis. *Arthritis Rheum* 1983, 26:500-508.
70. Drosos AA, Andronopoulous AP, Costopoulos JS, Stavropoulos ED, Pappadimitriou CS, Moustopoulos HM: Sjögren’s syndrome in progressive systemic sclerosis. *J Rheumatol* 1988, 15:963-968.
71. Kuwana M, Okano Y, Pardey JP, Silver RM, Fertig N, Medsger TA Jr: Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. *Arthritis Rheum* 2005, 52:2425-2432.
72. Yamazaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Nairn S, Richards HB, Chan EK, Reeves WH, Satoh M: Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. *Arthritis Rheum* 2006, 54:3051-3056.
73. Mahler M, Rajmankar R, Dahnrich C, Blühmer M, Fritzer MJ: Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. *Arthritis Rheum* 2005, 52:1904-1913.
74. Gilliam AC, Steitz JA: Rare scleroderma autoantibodies to the U1 small nuclear ribonucleoprotein and to the trimethylguanosine cap of U small nuclear RNAs. *Proc Natl Acad Sci USA* 1993, 90:6781-6785.
75. Feghali-Bostwick C, Medsger TA Jr, Wright TM: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. *Arthritis Rheum* 2003, 48:1965-1963.
76. Saunders WS, Chue C, Goebel M, Craig C, Clark RF, Powers JA, Eisenberg JC, Elgin SC, Rothfield NF, Earinshaw WC: Molecular cloning of a human homologue of *Drosophila* heterochromatin protein HP1 using anti-centromere autoantibodies with anti-chromo specificity. *J Cell Sci* 1993, 104:573-582.
77. Furuta K, Chan EK, Kyosawa K, Reimer G, Luderscheid C, Tan EM: Heterochromatin protein HP1H6 (p25B) and its localization with centromeres in mitosis. *Chromosoma* 1997, 106:11-19.
78. Dick T, Mierau R, Stemfeld R, Weiner EM, Genth E: Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). *J Rheumatol* 1995, 22:672-72.
79. Sztoczki C, Guldner HH, Netter HJ, Will H: Isolation and characterization of CDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. *J Immunol* 1990, 145:4338-4347.

Cite this article as: Mierau et al: Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. *Arthritis Research & Therapy* 2011 13:R172.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit